Bevacizumab in advanced ovarian cancer: when, what for and why?


Cite item

Full Text

Abstract

Treatment of advanced ovarian cancer remains a complex problem, which generates interest in researchers. Since there have been no changes in standard cytostatic treatment for last 20 years, addition of targeted drugs to the first-line therapy is considered to be a perspective approach. Currently the most examined group of targeted drugs in ovarian cancer is anti-angiogenic agents, with bevacizumab being one of the most intensively studied drugs in the field. This article analyses the results of the recent studies and the perspectives for the use of bevacizumab in advanced ovarian cancer.

About the authors

A S Tjulandina

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

канд. мед. наук, ст. науч. сотр. отд-ния клинической фармакологии и химиотерапии

References

  1. Тюляндин С.А., Покатаев И.А., Тюляндина А.С. и др. Лечение распространенного рака яичников: итоги работы отделения клинической фармакологии и химиотерапии РОНЦ РАМН им. Н.Н.Блохина за 1993-2010 гг. М.: Вестн. РАМН, 2011; 12: 4-9.
  2. Armstrong D, Bundy B, Wenzel L et al. Phase III randomized trial of intravenous cisplatin and paclitaxel vs an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin, and intraperitoneal paclitaxel in stage III ovarian cancer: a Gynecologic Oncology Group study. N Engl J Med 2006; 354: 34-43.
  3. Bansal G, Shulimovich M, Ratnarajah G et al. Clinical benefit and toxicity of continuing bevacizumab containing chemotherapies in patients with recurrent ovarian cancer. Cancer Therapy 2012; 8: 184-90.
  4. Bennouna J, Sastre J, Arnold D et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37.
  5. Burger R.A, Brady M.F, Bookman M.A et al. The incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-83.
  6. Chan J, Brady J.M, Penson R et al. Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin ± bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712). Int J Gynecol Cancer 2013; 23 (Suppl. 8). Abstr.
  7. Cohn A.L, Bekaii-Saab T, Bendell J.C et al. Clinical outcomes in bevacizumab treated patients with metastatic colorectal cancer: results from ARIES observational cohort study and confirmation of BRiTE data on BV beyond progression. J Clin Oncol 2010; 28 (Suppl. 15s). Abstr. 3596.
  8. du Bois A et al. AGO-OVAR 12: a randomized placebo - controlled gcig/engot - intergroup phase III trial of standard frontline chemotherapy ± nintedanib for advanced ovarian cancer. Int J Gynecol Cancer 2013; 23 (Suppl. 8). Abstr.
  9. Ebos J, Lee C.R, Cruz-Munoz W et al. Accelerated metastasis after short - term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-9.
  10. Ellis L.M, Hicklin D.J. VEGF-targeted therapy: mechanisms of anti - tumour activity. Nat Rev Cancer 2008; 8: 579-91.
  11. Fabi A, Russillo M, Ferretti G et al. Maintenance bevacizumab beyond first - line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor - positive metastatic breast cancer: efficacy in combination with hormonal therapy. BMC Cancer 2012; 12: 1-7.
  12. Gore M, Harrias M. Chemotherapy for epithelial ovarian cancer - treatment at first diagnosis. The Lancet Oncol 2002; 3: 529-36.
  13. Gridelli C, Bennouna J, Castro J et al. Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial. Clinical Lung Cancer 2011; 12 (6): 407-11.
  14. Grothey A, Sugrue M.M, Purdie D.M et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326-34.
  15. Jain R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
  16. Jayson G, Hicklin D, Ellis L et al. Antiangiogenic therapy - evolving view based on clinical trial results. Nat Rev Clin Oncol 2012; 14 (9): 297-303.
  17. Kassim S.K, El-Salahy E.M, Fayed S.T et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004; 37 (5): 363-9.
  18. Katsumata N, Yasuda M, Takahashi F et al. Dose - dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open - label, randomised controlled trial. Lancet 2009; 374: 1331-8.
  19. Masi G, Loupakis F, Salvatore L et al. Second - line chemotherapy with or without bevacizumab in metastatic colorectal cancer patients who progressed to a first - line treatment containing bevaizunab: Updated results of the phase III BEBYP trial by the Gruppo Oncologico Nord Ovest. JCO 2013; 31. Abstr. 3615.
  20. Mancuso M, Davis R, Norberg S et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Ivest 2006; 116 (10): 2610-21.
  21. Mannocci A, De Feo E, de Waure C et al. Use of trastuzumab in HER2- positive metastatic breast cancer beyond disease progression: a systematic review of published studies. Tumori 2010; 96: 385-91.
  22. Margolin K, Gordon M.S, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long - term safety data. J Clin Oncol 2001; 19: 851-6.
  23. Mc Cann G.A, Smith B, Backes F.J et al. Recurrent ovarian cancer: Is there a role for re - treatment with bevacizumab after an initial complete response to a bevacizumab - containing regimen? Gynecologic Oncol 2012; 127: 362-6.
  24. Neijt J.P, Engelholm S.A, Tuxen M.K et al. Exploratory phase III study of paclitaxel and cisplatin vs paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084-92.
  25. Oza A.M, Perren T.J, Swart A.M et al. ICON7: Final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. Eur J Cancer 2013; 49 (Suppl. 3): LBA6.
  26. Ozols R.F, Bundy B.N, Greer B.E et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected III stage, ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-200.
  27. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-31.
  28. Perren T.J, Swart A.M, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-96.
  29. Pignata S, Scambia G, Lauria R et al. A randomized multicenter phase III study comparing weekly versus every 3 week carboplatin plus paclitaxel in patients with advanced ovarian cancer: multicentre Italian trial on ovarian cancer (MITO-7): European Network of Gynecological Oncological Trial Group (ENGOT-ov-10). Gynecologic Cancer Inter Group (GCIG) trial. J Clin Oncol 2013; 31. Abstr. LBA 5501.
  30. Press J.Z, de Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA 1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8: 17.
  31. Pujade-Lauraine E, Hilpert F, Weber B et al. Bevacizumab Combined With Chemotherapy for Platinum - Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. JCO 2014; 32 (13): 1302-8.
  32. von Minckwitz G, Schwedler K, Schmidt M et al. Final overall survival analysis of the TBP phase III study (GBG 26/BIG 3-05): capecitabine vs capecitabine trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment. Cancer Res 2010; 70 (Suppl. 24): 459s. Abstr. P6-14-05.

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies